(+) Oncomed: Biocentury's NewsMakers In The Biotech Industry Conference (OncoMed) - Sep 29, 2013 - "Anti-Notch2/3 (OMR-59R5) summary"; "Potential GSK Opt-In Program"; "Ph1a study completed: Oral Plenary Presentation: Mol Targets and Cancer Therapeutics 2012"; "Safety: Well tolerated in refractory solid tumor patients"; "Toxicity: On-target diarrhea"; "Maximum tolerated dose (MTD) established for 3 dosing schedules (QW, Q2W,Q3W)"; "Efficacy: Prolonged stable disease"; "Triple Negative BC (JAG1 amplification), Liposarcoma, Adeniod Cystic Carcinoma, Rectal Cancer, Kaposi Sarcoma"
P1 data • Oncology • Pancreatic Cancer
|